Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has received an average rating of “Buy” from the six ratings firms that are currently covering the firm. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $22.00.

VNDA has been the subject of several recent analyst reports. Zacks Investment Research cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 18th. Jefferies Group LLC reissued a “buy” rating and issued a $23.00 price target on shares of Vanda Pharmaceuticals in a report on Sunday, January 8th.

Your IP Address:

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) opened at 14.15 on Tuesday. Vanda Pharmaceuticals has a one year low of $7.20 and a one year high of $18.00. The stock’s market capitalization is $627.50 million. The firm has a 50-day moving average price of $14.28 and a 200 day moving average price of $15.38.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, February 15th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.05. The business earned $38.24 million during the quarter, compared to analysts’ expectations of $39.38 million. Vanda Pharmaceuticals had a negative return on equity of 16.13% and a negative net margin of 23.07%. On average, equities analysts expect that Vanda Pharmaceuticals will post ($0.62) EPS for the current fiscal year.

In other news, SVP Richard L. Gulino sold 10,900 shares of the firm’s stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $15.51, for a total value of $169,059.00. Following the completion of the sale, the senior vice president now directly owns 12,500 shares of the company’s stock, valued at approximately $193,875. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 8.45% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. BlackRock Advisors LLC increased its position in Vanda Pharmaceuticals by 2.0% in the third quarter. BlackRock Advisors LLC now owns 98,663 shares of the biopharmaceutical company’s stock valued at $1,642,000 after buying an additional 1,907 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Vanda Pharmaceuticals by 26,149.8% in the third quarter. PNC Financial Services Group Inc. now owns 262,498 shares of the biopharmaceutical company’s stock valued at $4,368,000 after buying an additional 261,498 shares during the last quarter. Federated Investors Inc. PA increased its position in Vanda Pharmaceuticals by 1,102.3% in the fourth quarter. Federated Investors Inc. PA now owns 70,961 shares of the biopharmaceutical company’s stock valued at $1,132,000 after buying an additional 65,059 shares during the last quarter. Prudential Financial Inc. increased its position in Vanda Pharmaceuticals by 69.0% in the third quarter. Prudential Financial Inc. now owns 598,518 shares of the biopharmaceutical company’s stock valued at $9,959,000 after buying an additional 244,410 shares during the last quarter. Finally, Macquarie Group Ltd. increased its position in Vanda Pharmaceuticals by 24.6% in the second quarter. Macquarie Group Ltd. now owns 1,532,533 shares of the biopharmaceutical company’s stock valued at $17,149,000 after buying an additional 302,591 shares during the last quarter. 95.69% of the stock is owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

5 Day Chart for NASDAQ:VNDA

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.